Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

lly manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:  InvestorsEugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except for share and per share data)December 31, 2009 (1)September 30, 2010(unaudited)ASSETSCurrent assets:Cash and cash equivalents$

167,171$

127,539Short-term investments133,506224,428Accounts receivable, net73,54078,734Inventory78,66291,741Other current assets14,84831,747Total current assets467,727554,189Investment in BioMarin/Genzyme LLC4411,161Long-term investments169,84988,955Property, plant and equipment, net199,141213,755Intangible assets, net40,977104,604Goodwill23,72253,364Other ass
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... 14, 2007-Acceleron Pharma, Inc., a,biopharmaceutical company developing ... cancer-related diseases, today,announced results of a preclinical ... the compound to increase muscle mass,and strength ... of muscular,dystrophy. ACE-031 inhibits negative regulators of ...
... Biotechnology reports positive results from placebo,controlled phase ... dust,mite allergy , ,SCHLIEREN (Zurich), Switzerland, May ... today positive results from a multi-centre,and placebo-controlled ... an immunotherapeutic product candidate for the,treatment of ...
Cached Medicine Technology:Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies 2Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 2Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 4Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 5Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 6Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 7
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2
... ... care than other nations. Low back pain is the number two most common reason Americans ... spinal issues will now be able to see, touch and thereby better understand common spinal ... Issaquah, WA ...
... new study finds that Hispanics live in areas ... for colorectal cancer screening. Published early online in ... American Cancer Society, the study indicates that differences ... explain why Hispanics are less likely to undergo ...
... Atomic Force Microscope depicts on its screen the few ... flexible sticks, crisscrossing the surface on which they are ... in fact that they can self assemble into complex ... and University of Fribourg have teamed up to take ...
... SCD Probiotics ... to bring aid to the people of Chile. Donations are currently being raised to ... Valparaiso where it will be used and distributed, primarily through the Chilean military., , ... (PRWEB) April 11, 2010 -- In ...
... boosts performance, study finds , FRIDAY, April 9 (HealthDay ... medication react more like other children when faced with ... researchers have found. , The findings, published in the ... that the medication does what it,s supposed to do: ...
... ... in the state, Dr. Jeffrey Raval has pioneered a new process to make the injections ... fillers, a practice that the FDA approved in 2009. , ... Denver, Colo. (PRWEB) April 10, 2010 -- As an injector ...
Cached Medicine News:Health News:Latest Resource From Dynamic Disc Designs Helps Physicians Educate Patients 2Health News:Latest Resource From Dynamic Disc Designs Helps Physicians Educate Patients 3Health News:Hispanics live in areas with limited capacity for colorectal cancer screening 2Health News:The assembly of protein strands into fibrils 2Health News:Beneficial Microorganisms Rescue Chilean Earthquake Victims 2Health News:Beneficial Microorganisms Rescue Chilean Earthquake Victims 3Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 2Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 3
1 mm wide by 28 mm long sterling silver blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Medicine Products: